Latest Headlines

Latest Headlines

Note to Pfizer: Bayer shopping for vet buys

Might Bayer be a potential buyer for Pfizer's ($PFE) animal health business? The German drugmaker wants to grow its animal health unit, research exec Andreas Busch tells Dow Jones. Part of that

As rumors swirl, Shire eyes Vyvanse for binge eating

Amid rumors that it's being targeted for takeover by Bayer, Shire is looking to develop its attention-deficit drug Vyvanse as a treatment for binge-eating disorder. The disorder is set to be

Bayer's Yasmin to face EU generics this year

Bayer's birth-control franchise suffered a blow in Europe as patent regulators yanked protection on Yasmin. As the company's second-best-selling drug, Yasmin could now face generic competition later

Bayer joins social media follies with tweet apology

Pharma's forays into social media have been tentative at best. Drugmakers never know when they'll take a step outside the lines. Consider Bayer, which was forced to apologize to U.K. watchdogs for

Xarelto gets boost from FDA

Despite the upcoming July 4 holiday weekend, FDA officials were busy Friday. In addition to approving a Novartis drug, they gave good news to Johnson & Johnson and Bayer Healthcare with the

Pfizer/BMS data poses threat to BI's Pradaxa

When several drugmakers are developing similar new drugs, there's always a lot of talk about which one will reach the market first. In the case of clot-busting drugs to compete with the old standby

UPDATED: Regeneron eye drug gets green flag at AdComm

Regeneron Pharmaceuticals ($REGN) has passed a key test at an FDA advisory committee meeting on its experimental eye drug. The expert panel voted unanimously that the treatment, called VEGF Trap-Eye,

High Court clears way for Baycol class action

Bayer will have to fight a potential class action suit over its cholesterol drug Baycol. The U.S. Supreme Court negated a Minnesota judge's ban on class actions over the drug, allowing two West

Are drugmakers suffering from complexity?

Complexity is generally considered to be a good thing. In business, companies that grow tend to become more complex; the former doesn't seem to be possible without the latter. But there's such a

'Bad complexity' hinders Bayer more than other firms

GlaxoSmithKline and Sanofi have lower levels of "bad complexity" than Novartis, J&J, Pfizer and Roche. But it's Bayer that struggles the most with excessive complexity, says a report from the